CHARLOTTE, N.C., Nov. 12, 2007 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Droxidopa, an orally active synthetic precursor of norepinephrine currently approved and marketed in Japan for the treatment of orthostatic hypotension. This IND acceptance will permit Chelsea to commence its pivotal Phase III clinical trials in neurogenic orthostatic hypotension (NOH).
